Melanom

Neoadjuvante Therapie

This is a preview of subscription content, access via your institution.

Literatur

  1. 1.

    Rozeman EA et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicenter, phase 2, randomized, controlled trial. Lancet Oncol 2019 20: 948-60

  2. 2.

    Rozeman EA et al. Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma. J Clin Oncol.2020; 38 (Suppl): Abstr 10015

  3. 3.

    Blank CU et al. First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol 2020; 38 (Suppl): Abstr 10002

  4. 4.

    Schermers B et al. Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. Br J Surg 2019; 106: 519-22

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Prof. Dr. med. Axel Hauschild.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hauschild, A. Neoadjuvante Therapie. hautnah dermatologie 37, 14–17 (2021). https://doi.org/10.1007/s15012-021-6602-3

Download citation